Selective A2a receptor agonists as inhibitors of cellular activation

Abstract

Four patent applications claim 2-(6-alkylamino-2-aminoalkylamino-purin-9-yl) -5-heterocyclylmethyl-tetrahydrofuran-3,4-diol derivatives. These applications differ in the heterocyclic substituents claimed, all of which are five membered azacycles. The 2,6-disubstitution provides compounds that are selective adenosine A2a receptor antagonists that are claimed to be useful in the treatment of asthma and COPD.

• adenosine A1 receptor
• adenosine A2a receptor
• asthma
• COPD
• purine